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Methods. We examined 127 families (204 patients) with theEstablishing an algorithm for molecular genetic diagnostics in
presumed diagnosis of NPH using molecular genetic diagnostic127 families with juvenile nephronophthisis.
techniques. In 68 families, renal biopsy was performed and wasBackground. Juvenile nephronophthisis (NPH1), an autoso-
consistent with NPH, and in 61 families, there was more thanmal recessive cystic disease of the kidney, represents the most
one affected child (“multiplex families”).common genetic cause of end-stage renal disease in the first
Results. In 74 families (115 patients), there was proof of thetwo decades of life. On the basis of identification of the gene diagnosis of NPH1 by detection of a homozygous deletion of
(NPHP1) defective in NPH1 and the presence of homozygous the NPHP1 gene, and in 5 families a heterozygous deletion in
deletions of NPHP1 in the majority of NPH1 patients, molecu- combination with a point mutation in NPHP1 was demon-
lar genetic diagnosis for NPH1 is now possible. Molecular ge- strated. Furthermore, for 16 families, NPH1 was excluded with
netic testing offers the only method for definite diagnosis of high likelihood by linkage analysis, and for 20 families by detec-
NPH1 and avoids invasive diagnostic measures like renal biopsy. tion of heterozygosity for two newly identified polymorphic
markers within the deletion region. In 5 of the remaining 12
families, which were noninformative for these markers, fluo-
rescence in situ hybridization did not detect any further hetero-
1 Members of the Study Group of the Arbeitsgemeinschaft fu¨r Paedia- zygous deletions.
trische Nephrologie (APN) in Germany are: (Berlin) G. Filler, H.H. Conclusions. The diagnosis of NPH1 was proven by molecu-
Neumayer, U. Querfeld; (Bremen) H.J. Bachmann; (Erlangen), W. lar genetic techniques in 62% of families with one or more
Rascher, M. Bo¨swald, B. Sterzel; (Essen) C. Feldhoff, K.-E. Bonzel, children with the presumed diagnosis of NPH. We presentM. Wingen, P. Hoyer, U. Vester, E. Passarge; (Frankfurt) J. Dippel, M.
evidence that there is a fourth locus for NPH, since only 6 ofSchro¨der; (Freiburg) M. Brandis, L.B. Zimmerhackl, H.P.H. Neumann;
the 26 multiplex families in whom the diagnosis of NPH1 was(Hamburg) H. Altrogge, D.E. Mu¨ller-Wiefel, J.-D. Schwarke; (Hanno-
excluded were compatible with linkage to other loci for NPH.ver) U. Bode, J. Brodehl, A. Bo¨kenkamp, J. Ehrich; (Heidelberg) O.
Mehls, K. Scha¨rer, R. Waldherr; (Homburg/Saar) H. Ko¨hler; (Jena) On the basis of the presented data, we propose an algorithm
J. Misselwitz, U. John, I. Hansmann; (Karlsruhe) F. Schindera, K. for molecular genetic diagnostics in NPH.
Ku¨hn; (Ko¨ln) B. Hoppe, D. Michalk; (Leipzig) Ch. Greiner; (Magde-
burg) D. Wiemann; (Mainz) R. Beetz; (Memmingen) R. Burghard;
(Meschede) J. Horst; (Mu¨nchen) B. Klare; (Mu¨nster), M. Bulla; (Reut-
lingen) B. Braun; (Rostock) H.-J. Stolpe, M. Wigger; (Stuttgart) H.M. Juvenile nephronophthisis, also termed nephronoph-
Leichter and (Zwickau) Th. Stuckert. APN members outside of Ger- thisis type 1 (NPH1), is an autosomal recessive cystic
many are: (Prague, Czech Republic) E. Semanova; (Tartu, Estonia) K.
kidney disease that constitutes the most common geneticOunap; (Helsinki, Finland) S. Ala-Mello; (Paris, France) C. Antignac;
(Genova, Italy) G.M. Ghiggeri, R. Gusmano; (Auckland, New Zealand) cause of end-stage renal disease in children [1–4]. The
I. Winship; (Umea, Sweden) E. Holmberg; (Zurich, Switzerland) E. disease leads to end-stage renal failure at a median age
Leumann, T. Neuhaus, A. Schinzel; (Maastricht, The Netherlands) R.H.
of 13 years [5]. For the diagnosis of NPH1, a historyKuijten; (Rotterdam, The Netherlands) K. Cransberg; (Istanbul, Tur-
key) A. Nayir, (Ankara, Turkey) R. Topaloglu, (Antalya, Turkey) E. of polyuria, polydipsia, anemia disproportionate to the
Bahat; (Birmingham, AL, USA) L. Guay-Woodford; (Cleveland, OH, degree of renal failure, and growth retardation is indica-
USA) B. Brouhard; (Durham, NC, USA) J. Foreman; (Pittsburgh, PA,
tive. Renal ultrasound shows normal kidney size, lack ofUSA) N. Weichler; (Miami, FL, USA) A. Paredes; (Dunwoody, GA,
USA) S. Jernigan; and (Vienna, Austria) E. Balzar, Ch. Aufricht. corticomedullary differentiation, increased echogenicity,
and later in the course of the disease cysts at the cortico-Key words: NPH1 and 2, cystic kidney disease, end-stage renal disease,
medullary border of the kidneys [6–9]. As an additionalnoninvasive diagnosis, nephronophthisis type 1, polyuria, childhood
anemia. diagnostic tool, renal function scintigraphy has been de-
scribed showing a characteristic concentrating defect inReceived for publication May 2, 2000
nephronophthisis [10, 11].and in revised form August 24, 2000
Accepted for publication August 28, 2000 Using positional cloning we recently identified the
gene responsible for NPH1 (NPHP1) [12, 13]. AlthoughÓ 2001 by the International Society of Nephrology
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little is known about the pathogenesis by which a defect (NPH2) is localized to 9q22-q31 and leads to end-stage
renal disease in infancy [25, 26]. Since histology in NPH2in NPHP1 leads to nephronophthisis, the fact that the
NPHP1 gene product nephrocystin encodes an SH3 (“src differs from the other forms of NPH, it is currently un-
clear whether this disease should be classified within thehomology 3”) domain [14, 15] points toward a potential
role of this gene product in protein/protein interactions, NPH/MCKD group of diseases. A gene locus for ado-
lescent nephronophthisis (NPH3) maps to 3q21-q22 [56].for example, in signal transduction at focal adhesions,
the contact points between cells and extracellular matrix Recessive juvenile nephronophthisis can be associated
with extrarenal organ involvement, like retinitis pig-[16, 17]. In addition, it has recently been shown that
nephrocystin interacts with p130Cas, which is a major mentosa in Senior–Løken syndrome (SLS) [27, 28], with
hepatic fibrosis [29], with cone-shaped epiphyses [30], orcomponent of focal adhesion signaling and has been lo-
calized also to cell–cell contacts at adherens junctions with cerebellar vermis aplasia and coloboma of the eye
in Joubert syndrome type B [31, 32]. NPH has also been(Otto et al, unpublished observations) [18]. A defect in
cell/matrix interaction would lend a potential explana- associated with Jeune syndrome [33–35] (asphyxiating
thoraxic dysplasia), Ellis van Creveld syndrome [36], andtion for the characteristic histologic picture of tubular
basement membrane disruption in NPH and to the find- RHYNS syndrome [37].
The second group of the NPH/MCKD group of dis-ing of altered integrin expression of renal tubular cells
in NPH [19]. It would also be in keeping with the finding eases is characterized by autosomal dominant inheri-
tance and late onset of end-stage renal failure, and isthat the knockout mouse model for tensin, another com-
ponent of focal adhesion signaling, histologically resem- associated with hyperuricemia and gout [38, 39]. These
diseases are termed “autosomal-dominant medullarybles human NPH [20].
Interestingly, in about 80% of children with NPH1, cystic kidney disease” (ADMCKD). Two different loci
are known so far: MCKD1 is localized on 1q21 [40], andthe disease is caused by deletions of the NPHP1 gene
on both parental chromosomes [5, 21]. The deletion is MCKD2 is localized on 16p12 [41]. There is additional
genetic locus heterogeneity [42–44].not due to a founder effect, but arises by homologous
recombination between two copies of a 45 kb direct re- Following identification of the NPHP1 gene as respon-
sible for NPH1, molecular genetic diagnosis can be per-peat, which flanks the NPHP1 gene [22]. In addition,
these authors have reported nonpathogenic rearrange- formed by demonstration of the presence of the deletions
or of point mutations in the NPHP1 gene (www.genetests.ments in patients and in controls that involved the large
inverted repeats flanking the NPHP1 gene [22]. Further- org) [12, 15, 45, 46]. In this study, we were able to firmly
establish the diagnosis of NPH1 by molecular genetic tech-more, we have recently cloned and characterized the
shortest deletion of NPHP1 reported thus far. It spans niques in 62% of families with one or more children with
the presumed diagnosis of NPH. On the basis of 127the region from intron 2 up to and beyond the 39 flanking
region of the gene, and occurs within a LINE1 element families (204 patients) examined, we propose an algo-
rithm for molecular genetic diagnostics in NPH. Further-[23]. Homozygous deletions of the NPHP1 region have
also been described in patients with NPH and ocular more, we present evidence that there is at least one
additional locus for isolated NPH, since there were 26motor apraxia-type Cogan (abstract; Saunier et al, Am
J Hum Genet 61:A346, 1997) [24]. However, the question multiplex families in whom we excluded the diagnosis
of NPH1 with a high likelihood.remains to why some patients present with isolated
NPH1 while others suffer from NPH1 in combination
with ocular motor apraxia-type Cogan, although there
METHODS
seems to be no distinction on a molecular genetic basis
Patients[22, 24].
Juvenile nephronophthisis (NPH1) belongs to a group Blood samples and pedigrees were obtained on the
basis of informed consent from 204 patients with theof diseases [nephronophthisis/medullary cystic kidney
disease (NPH/MCKD)] that share the characteristic re- presumed diagnosis of isolated NPH, representing 127
unrelated nuclear families. In most instances, blood sam-nal histologic triad of tubular basement membrane disin-
tegration, tubular atrophy with cyst development, and ples were also available from the parents. In 68 families,
the presumed diagnosis of NPH was based on a resultinterstitial cell infiltration with fibrosis. This histologic
pattern is characteristic but not pathognomonic for the from renal biopsy that was characteristic of NPH [47].
In the other families, the diagnosis was proposed by aNPH/MCKD group of diseases. For recessive forms, the
term “nephronophthisis” is used. For isolated nephron- (pediatric) nephrologist based on characteristic clinical
signs, such as polyuria, polydipsia, anemia, or growthophthisis, three different disease forms have been local-
ized to three different loci: Juvenile nephronophthisis retardation in the presence of incipient chronic renal
failure. In many instances, a result from renal ultrasound(NPH1) maps to chromosome 2q12-q13, and the gene
has been identified [12, 15]. Infantile nephronophthisis suggestive of NPH [6] was also available. In 61 families,
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Table 1. Sequences of oligonucleotides used in diagnosis of NPH1 as an internal positive control. Our prior study of eight
of the current families reported the detection of a homo-Primer Product
name Sequence (59 ! 39) length bp zygous deletion in the NPHP1 region [5].
146c2T-1 TGGCATTTTGGAAGTGCCTG 159 The absence of a large deletion in NPHP1 does not
146c2T-2 TGTGAAGGCATGAGCTCTGG completely exclude NPH1, since a homozygous or com-
9657T-1 TCTTCACGGAGGAGCACAGTC 211
pound heterozygous point mutation in NPHP1 might9657T-2 CCCAACTTTGCAAGCAGAAG
Wi-18516-1 ATAGGTTGTTATTTATGACTTGGGG 109 be present. However, statistically this situation is very
Wi-18516-2 GAAACCCTCTGATGGCATGT unlikely because the prevalence of NPH has been esti-
804/6-1 TTAAGCCCAAGTAACCATAGTC 215
mated to be one in 1 million inhabitants [51], and most804/6-2 GACAAATGGAATTAACGAAATA
146c2S-3 GTCAATCAAATGTGATACACC 133 cases are caused by homozygous deletions. Thus, the
146c2S-4b ATGACCGGATTTTGCTGAGAG allele frequency for an NPHP1 deletion will be less than
D2S1890-1 TTTCAGATCACCTAATGGGC 206–220
1 in 1000. Since in this study only one chromosome withD2S1890-2 AACTGTCTGGTCGGTCATTG
D2S1893-1 AACAAGGTGAGGCTCTGTC 244–264 an NPHP1 point mutation per 30 chromosomes with an
D2S1893-2 TCTAAAAATGAAGCAGGATACCA NPHP1 deletion (5 point mutations per 153 deletions)
9657T2N1 TGCATCTCTCTTCTGACTGGG 167
was found, the allele frequency for an NPHP1 point9657T2N2 TGTCTCTGATCAGAGGAACC
D2S1888-1 TTTGAAGTTTGGTGTCTGTGTAA 85–97 mutation (if they are treated indiscriminately) would
D2S1888-2 TGAAGTCCCTTGGAAATGTT be expected to be less than 1 in 30,000. Therefore, the
D2S160-1 TGTACCTAAGCCCACCCTTTAGAGC 204–218
likelihood of two point mutations of NPHP1 to occurD2S160-2 TGGCCTCCAGAAACCTCCAA
together, under the assumption of Hardy–Weinberg
equilibrium, would be about 1 in 900 million inhabitants.
For this reason, the absence of a heterozygous deletion
in NPHP1 can be taken as exclusion with high likelihoodthere was more than one child affected by NPH (“multi-
plex families”; Table 2, group A). As recommended [48], of NPH type 1.
we did not perform presymptomatic diagnosis, since no
Haplotype analysisapparent benefit results for the patient at a time point
in the course of NPH in which serum creatinine is still Highly polymorphic microsatellite markers that localize
to chromosome 2q were examined by radioactively la-normal. Patients were excluded from the study if the
presumed diagnosis was NPH in combination with extra- beled PCR followed by polyacrylamide gel electrophoresis
and autoradiography, and they were scored as describedrenal manifestations, like ocular motor apraxia-type Co-
gan [24], retinitis pigmentosa (Senior–Løken syndrome previously [5]. The following microsatellite markers were
employed in the haplotype analysis: D2S1890, D2S1893,[27, 28]), cerebellar vermis hypoplasia/aplasia (Joubert
syndrome Type B [31, 32]), hepatic fibrosis [29], Bardet– 9657T2N, D2S1888, and D2S160 (order from centromere
to telomere). Primer sequences are shown in Table 1.Biedl syndrome, or Jeune syndrome. The geographic
origin of these families was from Europe (Austria, Esto- All markers were from Genethon [52] with the exception
of 9657T2N. This marker is a polymorphic CA repeatnia, Finland, France, Germany, Italy, Lithuania, The
Netherlands, Sweden, Switzerland, and Turkey), North marker, which we newly identified within the 39-flanking
sequence of the NPHP1 gene by direct sequencing ofAmerica (United States), Asia (Russia), Australia (New
Zealand), India, and Africa (Togo). PAC clone 146c2. For polymorphic marker 9657T2N,
the 59 nucleotide of primer 9657T2N1 is located 1785 bp
Analysis for a homozygous NPHP1 deletion centromeric and primer 9657T2N2 is located 1952 bp
centromeric of the start codon of the first exon of theGenomic DNA was isolated by standard methods [49]
directly from blood samples or from Epstein Barr virus MALL (or BENE) gene [12].
(EBV)-transformed peripheral blood lymphocytes [50].
Screening for point mutations in NPHP1Analysis for a homozygous deletion of the NPHP1
gene was performed by polymerase chain reaction (PCR) Mutational analysis by single-strand conformational
polymorphism analysis (SSCP) was performed for all 20on genomic DNA of patients with NPH. One multiplex
PCR was performed with two markers localized within NPHP1 exons as described [12]. Direct sequencing of
SSCP products was done after purifying PCR-productsthe common NPHP1 deletion: 146c2T-1/2 [13] and
9657T-1/2 [5]. Primer sequences are shown in Table 1. with QIAquick spin columns (Qiagen, Hilden, Ger-
many) and sequenced directly on an automated fluores-As an internal positive control marker localized outside
of the deletion, we used Wi-18516-1/2 (GenBank acc. no. cent sequencer.
G24662). PCR was performed by radioactive multiplex
Fluorescence in situ hybridizationPCR as described previously [5]. Annealing temperature
in all cases was 588C. A second multiplex PCR was per- Fluorescence in situ hybridization (FISH) was per-
formed with P1-related artificial chromosome (PAC)formed with deletion markers 804/6 [21] and 146c2S-3/4b
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clones as described [53, 54]. The positive control probe only families with a biopsy-proven diagnosis were counted,
this number was 44%, which hinted that a certain numberPAC 9681, which is localized outside of the NPHP1
deletion, was biotinylated and detected via strepta- of the families with renal biopsy result available might
represent a form of NPH other than type 1 (Table 2,vidin-conjugated fluorescein. PAC probe 146c2, which
is localized within the NPHP1 deletion, was labeled with group B). At this point of the diagnostic work-up, 53
families, 29 of whom were multiplex, remained in thedigoxigenin and detected via rhodamine-conjugated
antidigoxigenin. study (Table 2, group B).
Haplotype analysisScreening for a heterozygous NPHP1 deletion
Two PCR primer pairs that we had used previously Since linkage analysis can be employed to exclude
(although not prove) the diagnosis of NPH1 [5], we per-to amplify NPHP1 exon 7 and intron 9 [12] were found
to exhibit a diallelic polymorphism on SSCP. For the formed haplotype analysis for linkage to the NPHP1
locus in the remaining 29 multiplex families. By haplo-exon 7 polymorphism, primers EX7F and EX7R were
employed as described previously [12]. The polymor- type analysis, 16 multiplex families (12 biopsy proven)
were excluded from linkage to NPHP1, representing 38phism involves a silent nucleotide exchange 654A!G
with relatively equal distribution of both alleles in the patients (Table 2, group C). These patients most likely
suffer from a form of isolated NPH other than type 1.population examined. This base exchange can be de-
tected by abolishing a Tfi I restriction site. For intron 9, This appears even more likely, since later some of these
families were found to be compatible with linkage toprimers EX10F and EX10R were used as described pre-
viously [12]. The polymorphism involves a IVS9-47T!C NPHP3 (Omran et al, personal communication). Since
none of the patients enrolled entered end-stage renalexchange with relatively equal distribution of both alleles
in the population examined. Both polymorphisms are disease within the first three years of life, infantile neph-
ronophthisis (NPH2) can also be excluded. At this pointpositioned within the large deletion described in NPH1.
of the diagnostic work-up, 37 families (26 with renalTherefore, if an affected child is heterozygous for at least
biopsy result and 13 multiplex) remained in the study,one of the two polymorphic markers, a large heterozy-
representing 51 patients (Table 2, group C). Amonggous deletion can be excluded. In some patients, only
these, we expected a significant number to harbor a het-one allele was seen in both markers. In this case, we also
erozygous deletion, since the initial analysis for a homo-examined the parents to determine whether there was
zygous NPHP1 deletion was positive in 44% of all fami-parental noncontribution for one allele, demonstrating
lies with a renal biopsy result compatible with NPH.the presence of a heterozygous deletion or whether the
Therefore the affected children of the 37 remaining fami-marker was noninformative in this family.
lies were screened by SSCP of all 20 NPHP1 exons as
described [12], and direct sequencing performed if the
RESULTS SSCP pattern suggested a point mutation.
A total of 127 families with suspected NPH in at least
Screening for point mutations in NPHP1one member was enrolled in the molecular genetic diag-
nostic study on NPH1. For 68 families, the diagnosis of Two families with novel point mutations were detected
NPH had been confirmed by renal biopsy. In 61 families, that occurred hemizygously in combination with a het-
there was more than one child affected with NPH (“mul- erozygous deletion: In family F41, the affected child car-
tiplex families”), amounting to a total of 204 patients ried a maternally inherited heterozygous deletion of
within the study (Table 2, group A). NPHP1 in combination with a paternally inherited point
mutation in exon 9 (Fig. 1). The mutation (1024G!A)
Analysis for homozygous NPHP1 deletion leads to a nonconservative G342R exchange, affecting
Since the presence of a homozygous deletion of the an amino acid, which is conserved in nephrocystin of
NPHP1 gene can be taken as proof for the diagnosis of mouse [14] and dog [18], but not in C. elegans [14].
NPH1 [12, 21, 22], we performed as a first diagnostic In addition, this nucleotide exchange affects an 80%
step deletion detection by PCR using three markers from conserved splice donor consensus [55] and thus most
within the deletion, together with two control markers likely interferes with correct splicing. This point muta-
from outside the deletion region, as described in the tion was not seen in 70 healthy controls. The results from
Methods section. We detected a homozygous deletion family F41 are shown for SSCP and direct sequencing
in the affected children of 74 families (30 with renal in Figure 1 A and B, respectively.
biopsy result), 32 of whom were multiplex families, rep- In the affected child of family 275, in exon 6 we de-
resenting a total of 115 patients (Table 2, group B). Thus, tected an insertional mutation (548insA), which induces
as a result of deletion analysis, the diagnosis of NPH1 a frame shift, leading to an in-frame STOP codon four
amino acids downstream (D187X; Fig. 2). The motherwas firmly established in 58% of all families enrolled. If
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Table 2. Diagnostic work-up using molecular genetics in 127 families with presumed isolated juvenile nephronophthisis (NPH1)
Molecular genetic diagnosis of NPH1 Families a(histology)
b [multiplex] c Cumulative numberExcluded Proven
and patients of families with
Families a (histology) Families a (histology) remaining in the molecular genetic
Results from diagnostic tests for NPH1 b [multiplex] b [multiplex] diagnostic work-up proof of NPH1
Group (work-up proceeds from top to bottom) patients patients for NPH1 a (histology) in %
A Total families enrolled 127 (68)
— — [61] —
204
B Homozygous NPHP1 deletion detected 74 (30) 53 (38) 74 (30)
— [32] [29] 58% (44%)
115 89
C Linkage to NPHP1 excluded by haplo- 16 (12) 37 (26)
type analysis in multiplex families [16] — [13] —
38 51
D Heterozygous deletion with heterozy- 5 (4) 32 (22) 79 (34)
gous point mutation detected by — [3] [10] 62% (50%)
direct sequencing 8 43
E Large heterozygous deletion excluded, 20 (15) 12 (7)
since patient heterozygous for exon 7 [8] — [2] —
or intron 9 polymorphism 29 14
F Large heterozygous deletion not 12 (7)
excluded, since patient homozygous — — [2] —
for exon 7 or intron 9 polymorphism 14
G Large heterozygous deletion excluded 5 (2) 7 (5)
by FISH [2] — [0] —
7 7
a Number of families in whom renal histology was performed and compatible with NPH
b Number of “multiplex” families (i.e., with more than 1 affected child)
c Cumulative number of families, in whom the diagnosis of NPH1 was established in the course of molecular genetic diagnostics
was heterozygous, and the affected child was hemizygous hemizygous point mutation (IVS14 1 1delG; Fig. 4) with
a paternal heterozygous deletion [12]. Together with thefor this point mutation, since he inherited a paternal
deletion. This insertional mutation was absent from the three hemizygous point mutations described previously
[5], five hemizygous point mutations were detectedhealthy control and from the father, who heterozygously
carried a deletion of this region. It was also absent from within the 37 families studied by SSCP.
70 healthy controls. The results from SSCP and direct
Analysis for heterozygous NPHP1 deletionsequencing are shown for family 275 in Figure 2A and
B, respectively. In addition, in two families, we detected Detection of homozygous NPHP1 deletions in 74 fam-
ilies and of heterozygous deletions with hemizygoustwo base changes within intron 16 (IVS16 1 19C!T and
IVS16 1 38T!A; data not shown). Although these base point mutations in five families (4 with renal biopsy re-
sult, 3 multiplex) has lead to the definite diagnosis ofchanges were not detected in 70 healthy individuals, they
most likely represent innocuous polymorphisms, since NPH1 in 79 families (Table 2, group D). At this point
of the diagnostic work-up, 32 families (22 with renalthey are not part of a conserved splice consensus. We have
previously described three additional point mutations in biopsy result), 10 of which were multiplex, remained to
be classified by molecular genetic diagnostic techniquesNPHP1 in combination with a heterozygous deletion
[12]. Therefore, the two novel point mutations described (Table 2, group D).
Since all deletions in NPH1 described so far extendhere add up to a total of five families (4 biopsied) found
within the cohort examined (Table 2, group D). across the NPHP1 gene at a minimum from exon 3 to
exon 20 [12, 22], two newly detected di-allelic SSCPIn the NPHP1 point mutations described, it was possi-
ble to delineate clearly the parental origin of the hetero- polymorphisms were employed, one in exon 7 and one
in intron 9 (Methods section), to exclude the presencezygous deletion from SSCP and direct sequencing data
by the absence of one parental allele in the affected child of a heterozygous deletion in the remaining families. In
20 families (15 with renal biopsy result, 8 multiplex), the(Figs. 1 and 2). However, we sought to demonstrate
directly the presence of the heterozygous NPHP1 dele- affected child was heterozygous for at least one of the
two polymorphisms. Since in the case of a heterozygoustion by FISH in families in which material was available
for preparation of metaphases. As an example, Figure deletion the parental noncontribution of one allele would
have to be found, the state of heterozygosity in the af-3 shows the result from FISH in family F40, in whom we
have previously described the combination of a maternal fected child excluded the presence of a heterozygous
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NPHP1 deletion in these families (Table 2, group E).
Because the chance that two compound heterozygous
point mutations are found in NPH is very low, nephron-
ophthisis type 1 is excluded with great certainty in these
families. The facts that in 15 of these families renal histo-
pathology was consistent with NPH and that 8 families
had multiple affected children corroborate the diagnosis
of NPH, rendering it very likely that these patients suffer
from a form of isolated NPH other than type 1.
Following exclusion of a heterozygous large deletion
of the NPHP1 gene in 20 families (29 patients), in whom
the affected children were heterozygous for one of the
two polymorphic markers, 12 families (7 with renal biopsy
result, 2 multiplex) remained for diagnostic work-up (Ta-
ble 2, group F). In these families, the affected children
carried only one allele of the exon 7 and intron 9 poly-
morphisms, respectively, and no parental noncontribu-
tion could be demonstrated in these children. Since this
finding cannot be discerned from noninformativity for
the marker, NPH1 could neither be excluded nor proven
for these families.
In five of these families, blood samples of EBV-trans-
formed lymphocytes for FISH were available. We there-
fore examined the affected children for a heterozygous
NPHP1 deletion by FISH analysis in the same way as
described for family F40 (Fig. 3). However, no heterozy-
gous deletion was detected in any of the five families (2
with renal biopsy result, 2 multiplex), making it very
likely that these patients suffer from a form of isolated
NPH other than type 1 (Table 2, group G). Finally, seven
families (5 biopsy proven, no multiplex), in whom no
material for FISH was available, remained unsolved.
From these data, we conclude that molecular genetic
diagnosis is a useful tool to prove or exclude with high
likelihood the presumed diagnosis of NPH1. The fact
that in our cohort there were 26 multiplex families in
whom NPH1 was excluded with high likelihood, while
only six were compatible with linkage to NPHP3, indi-
cates that there is at least one additional locus for NPH.
DISCUSSION
In this study of 127 families with presumed isolated
NPH (68 with renal biopsy result, 61 multiplex), we were
able to prove the diagnosis of NPH1 by demonstrating
a homozygous deletion in 74 families (58%) or by de-Fig. 1. Point mutation in exon 9 of the NPHP1 gene in family F41.
tecting a heterozygous deletion in combination with a(A) SSCP shows a normal pattern in a healthy control and in the mother,
who carries on one chromosome a deletion of this genetic region. In point mutation in five families (4%), amounting to a
the father, there is a band shift resulting from a point mutation. This total of 79 families (62%). In 41 families (32%; 29 withband shift occurs hemizygously in the child, since no product results in
renal biopsy result, 26 multiplex), we excluded NPH typethis child from the maternal chromosome, which carries the deletion.
(B) Direct sequencing of the exon 9 splice donor junction reveals hetero-
zygously in the father a G1024A exchange, which changes the codon
(G_splice_gt) for a conserved glycine at position 342 into the codon
(A_splice_gt) for an arginine, and in addition affects an 80% conserved in one chromosome. The affected child is hemizygous for this point
mutation, since he inherits a maternal deletion. Exonic nucleotides aresplice donor consensus. This G1024A exchange is absent in the healthy
shown as capitals and intronic nucleotides as lower case letters.control and in the mother, who carries a deletion of this region
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1 by demonstrating the absence of a linkage to NPHP1
or excluded it with high likelihood by demonstrating the
absence of a heterozygous deletion. Seven families (6%)
remained unsolved. To our knowledge, this represents
the largest study on molecular genetic diagnostics in
NPH reported to date.
Percentage of families with NPH1
Formerly, the only method to discern NPH1 from non-
NPH1 was linkage analysis. Since linkage can only be
assessed in multiplex families or in families with consan-
guinity, only kindred fulfilling these criteria can be used
for comparison between studies. In addition, in small
families, linkage is only suggestive for the diagnosis but
does not prove the diagnosis. Konrad et al have pre-
viously described large-scale rearrangements in 80% of
the patients belonging to inbred or multiplex NPH1 fami-
lies and in 65% of the sporadic cases [21]. In a previous
study, we have shown compatibility with linkage to
NPHP1 only in 10 out of 16 families with NPH (62%)
[5]. For the study presented here, if only multiplex and
consanguineous families are considered, there was a ratio
of 16 out of 68 (24%) families in whom linkage to NPHP1
was excluded with high likelihood. Thus, the ratio of
families that were compatible with linkage to NPHP1
(76%) is again lower than the ratio of 80% of families
with deletions of the NPHP1 locus described for familial
cases by Konrad et al [21].
Since this study extended molecular genetic diagnos-
tics to sporadic cases by means of detection of heterozy-
gous deletions and/or point mutations in NPHP1, we
were able to assess the number of all families, regardless
of the presence of multiple or single affected individuals.
The diagnosis of NPH1 was excluded in 41 of 127 families
(32%), and vice versa the diagnosis was confirmed in 79
of 127 (62%), while 7 (6%) were inconclusive. These
data demonstrate that 68% of all families examined at
most represent NPH1, while about one third of all fami-
lies must harbor a genetic form other than NPH1. This
finding is novel and somewhat surprising. However, if
only the group with the most stringent diagnostic criteria
is considered, that is, families in which data from renal
biopsy were compatible with NPH, this finding is con-
firmed. In this group, the diagnosis of NPH1 was con-
firmed by molecular genetic techniques only in 34 out
of 68 families (50%), while it was excluded with high
Fig. 2. Point mutation in exon 6 of the NPHP1 gene in family F275. likelihood in 29 out of 68 families (43%). The relatively
(A) SSCP shows a normal pattern in a healthy control and in the father,
who carries on one chromosome a deletion of this genetic region. In
the affected child, there is a band shift to a slightly longer band, which
is seen heterozygously in the mother. The aberrant band occurs hemizy-
gously in the child, since no product results in this child from the
paternal chromosome, which carries the deletion. (B) Direct sequencing is hemizygous for this point mutation, since he inherits a paternal
of exon 6 reveals heterozygously in the mother an insertional mutation deletion. This insertional mutation is absent from the healthy control
(548insA), which induces a frame shift, leading to an in-frame STOP and from the father, who carries a deletion of this region in one chro-
codon four amino acids downstream (D187X). The affected child mosome.
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low percentage of homozygous deletions detected might
also be due to the fact that histopathology was not evalu-
ated by a single pathologist.
The 16 multiplex families in whom NPH1 was ex-
cluded by linkage analysis (Table 2, group C) exhibit
three strong diagnostic criteria for NPH: (1) history and
clinical signs compatible with NPH, (2) renal histology
characteristic of NPH in 12, and (3) familiarity in all of
them. Since linkage to NPHP1 was excluded in these
families, they must represent families with a form of
isolated NPH other than type 1. In addition, there were
eight multiplex families in whom no homozygous or het-
erozygous deletion of NPHP1 was found (Table 2, group
E), and two multiplex families in whom no heterozygous
deletion was found by FISH (Table 2, group F). Thus,
we identified 26 families altogether (20 with renal biopsy
result) in whom NPH type 1 was excluded with a high
likelihood. Only six of these families were compatible
with linkage to NPHP3 (Omran et al, personal communi-
cation). The median age for onset of ESRD in these six
families was 20 years (range 11 to 20 years), which is
compatible with the described median age of 19 years
in NPH3 [56]. Since no cases of NPH2 were included in
the study, we therefore consider it quite likely that at
least one additional locus for isolated NPH exists.
Point mutations in NPHP1
The mutations found in this study, together with all
mutations described so far in patients with NPH1, are
summarized in Figure 4 in relationship to a map of puta-
tive secondary structure of the NPHP1 gene product
nephrocystin. Seven additional potential loss-of-function
point mutations in combination with a heterozygous
NPHP1 deletion have been reported previously. We
have described maternally-derived point mutations in
exons 2, 14, and 18 [12]; Saunier et al described mutations
in exons 9 and a point mutation in exon 10 [15], and
Caridi et al have described point mutations in exons 15
and 17 [46].
The point mutations in exons 2, 6, and 17, and within
b
Fig. 3. FISH analysis for a heterozygous NPHP1 deletion in family
F40. PAC clone 9681 (fluorescein stained) is localized outside of the
deletion region and was used as a positive control. It yields a signal on
both chromosomes 2q12-q13. PAC clone 146c2 (rhodamine stained) is
localized within the NPHP1 deletion and therefore is absent in case of
a deletion. (A) The healthy control carries no heterozygous NPHP1
deletion and therefore yields a signal with both PAC clones on both
homologous chromosomes 2. (B) The mother carries a heterozygous
point mutation and therefore yields a signal with both PAC clones on
both chromosomes 2 [12]. (C) The affected child inherits a point muta-
tion from the mother but a deletion from the father. Therefore, a signal
for PAC clone 146c2 is seen only on the maternal chromosome of this
affected child, while the positive control PAC 9681 yields a signal on
both chromosomes 2.
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Fig. 4. Model of secondary structure for nephrocystin, the product of the NPHP1 gene. (A) Putative domains of nephrocystin as derived from
database searches [14]. (B) Graphical representation of putative nephrocystin domain structure. “PXXP” denotes SH3-binding consensus sequence.
(C) Exon-intron boundaries in human NPHP1 in relationship to putative domain structure in human (connected by vertical dashed lines). (D)
Human amino acid sequence numbering in relationship to exons. (E) Summary of all point mutations in NPHP1 described so far. All are found
hemizygous in combination with a heterozygous deletion in patients with NPH1. Positions in relationship to exons are denoted by vertical lines.
Point mutation nomenclature is used as recommended [57]. Nucleotide and amino acid numbering is in accordance with GenBank accession No.
NM_000272, which is shorter by one amino acid when compared with accession No. AF023674 because of the lack of one glutamine codon at
amino acid position 313. aThis study. bFrom Hildebrandt et al [12]. cFrom Saunier et al [15]. dFrom Caridi et al [46].
introns 10, 14, and 18 were of maternal origin. The exon according to an old nucleotide and amino acid number-
ing; note Fig. 4 legend]. The question remains unan-9 mutation was of paternal origin, while the point muta-
tions in exons 15 [46] and 9 [15] occurred de novo in the swered as to why some patients show the symptoms of
ocular motor apraxia in addition to the clinical pheno-affected child. All of these point mutations occurred
as hemizygous point mutations in combination with a type of NPH1, despite that there seems to be no distinc-
tion on a molecular genetic basis [22, 24].heterozygous deletion. Currently, no patient with two
homozygous or two compound heterozygous point muta-
Diagnostic algorithmtions in NPHP1 has been described. This is expected
given the relatively small number of point mutations A major problem in the management of patients with
suspected juvenile nephronophthisis is the difficulty ofdescribed to date. It is interesting to note that all point
mutations found in NPHP1 are very likely loss-of-func- firmly establishing the correct diagnosis, based on the
fact that symptoms are relatively mild and renal ultraso-tion mutations, since they involve nonsense mutations,
obligatory splice site mutations, and missense mutations nographic findings and even histology are characteristic
but not pathognomonic [47]. In this study, a number ofleading to nonconservative amino acid exchanges. Their
localization is distributed over the different domains of noninvasive diagnostic tests requiring a blood sample
only are described, which provide novel tools for estab-nephrocystin.
All point mutations have been found to be unique to lishing or confirming the diagnosis of NPH1. With the
help of such tests, the notorious problem of establishingonly one family with the exception of the 1024G!A
substitution (G342R). We have previously found this a correct diagnosis can be relieved at least for the cases
with deletion-positive NPH1, which constitute about twomutation hemizygously and derived from the maternal
allele in a patient with NPH1 and ocular motor apraxia- thirds of all NPH patients. From the experience with
molecular genetic diagnostics in the 127 families de-type Cogan syndrome [24]. [In this publication, the same
mutation was denoted 1027G!A substitution (G343R) scribed, we propose an algorithm for the diagnostic
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Fig. 5. Algorithm for molecular genetic diagnostics in NPH. a(www.genetests.org).
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(ZKF1-A1), and by the State of Baden-Wuerttemberg (FSP “Zysto-work-up of patients with the presumed diagnosis of NPH.
genese”).This algorithm is shown in detail in Figure 5. This molec-
ular genetic approach, as opposed to the invasive proce- Reprint requests to Friedhelm Hildebrandt, M.D., University Chil-
dren’s Hospital, Mathildenstrasse 1, D-79106 Freiburg, Germany.dure of renal biopsy, allows definite diagnosis of NPH1
E-mail: hildebra@kkl200.ukl.uni-freiburg.dein case a deletion is found. According to our presented
data, this can be expected in about two thirds (62%) of
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